Cutibacterium

Photodisinfection Found to Eradicate Biofilms Associated With Periprosthetic Joint Infections

Retrieved on: 
Tuesday, January 17, 2023
Biotechnology, Infectious Diseases, Health, Pharmaceutical, Clinical Trials, PDT, Infection, ESKAPE, Photosensitizer, Teaching hospital, AIM, Staphylococcus epidermidis, Internal medicine, Staphylococcus, Staphylococcus aureus, Biofilm, Escherichia coli, University Hospital of Zürich, Disease, Mortality, Research, Antibiotic, Pharmaceutical industry, Cutibacterium

A new study published in the journal Antibiotics found that antimicrobial photodisinfection therapy (aPDT), using Ondine Biomedical Inc.’s (AIM: OBI) proprietary methylene blue-based photosensitizer in combination with a specific wavelength of light, effectively eradicated pathogen biofilms commonly associated with periprosthetic joint infections (“PJIs").

Key Points: 
  • A new study published in the journal Antibiotics found that antimicrobial photodisinfection therapy (aPDT), using Ondine Biomedical Inc.’s (AIM: OBI) proprietary methylene blue-based photosensitizer in combination with a specific wavelength of light, effectively eradicated pathogen biofilms commonly associated with periprosthetic joint infections (“PJIs").
  • The results of this study suggest that photodisinfection could be used as an effective treatment method for PJIs, replacing current, more invasive approaches and potentially shortening antibiotic treatment.
  • This would not only improve patients’ quality of life, but also reduce morbidity, mortality, antibiotic resistance, and the high healthcare costs associated with treating these infections.
  • The in vitro study, conducted by a research team from University Hospital Zurich, found that photodisinfection achieved 100% kill of the key pathogens in biofilms associated with PJIs.

LexaGene Successfully Completes Statement of Work for BioPharma Company

Retrieved on: 
Tuesday, November 22, 2022
COVID-19, Staphylococcus, LXG, Streptococcus, Escherichia coli, Risk, TSX Venture Exchange, Legislation, System, Gold, PCR, SEDAR, News, Genetic testing, Mycoplasma, OTCQB, Safety, Medical device, Cryptocurrency, Risk management, Cutibacterium

Furthermore, the data proved the MiQLab System is comparable to gold standard techniques performed by skilled scientists.

Key Points: 
  • Furthermore, the data proved the MiQLab System is comparable to gold standard techniques performed by skilled scientists.
  • The study was conducted mainly at LexaGene except for using proprietary materials from the biopharma company, as these tests were performed by employees of the biopharma company at their location using their recently purchased MiQLab System.
  • For more information about LexaGene and the MiQLab System, please visit www.lexagene.com or follow us on Twitter and LinkedIn .
  • LexaGene is a molecular diagnostics company that has commercialized the MiQLab System for fast and easy detection of biological contaminants, pathogens and other molecular markers.

Key patent issued on Eligo's gene editing breakthroughs applied to skin disorders

Retrieved on: 
Tuesday, November 15, 2022
GlaxoSmithKline, Acne, CRISPR, Gene editing, Maintenance, Hair follicle, European Commission, Skin, B cell, Gene, Efficiency, Genetic engineering, Khosla Ventures, US, MIT, Bacteria, Patent, Program, Technology, Patient, Rockefeller University, World Economic Forum, Inflammation, Vaccination, Skin cancer, Vitiligo, Immune system, Royal commission, Science, C, United States patent law, Hair, Antibiotics, Pharmaceutical industry, Vaccine, Cutibacterium

This pioneering work also provides unique opportunities to leverage the skin's immune system for oncological, vaccination or desensitization applications.

Key Points: 
  • This pioneering work also provides unique opportunities to leverage the skin's immune system for oncological, vaccination or desensitization applications.
  • No genetic toolbox was yet in existence for this notoriously difficult-to-engineer bacterial species before Eligo achieved these long-awaited genetic engineering breakthroughs.
  • C. acnes is a key and ubiquitous species of the skin microbiome that provides many health benefits for the host, such as maintenance of skin barrier and protection against pathogens.
  • Patent family WO2022096596 fully supports Eligo's acne program and many other serious skin disorders such as skin cancer, alopecia and vitiligo, as well as a tool for potential vaccination and desensitization.

Sanofi to acquire Origimm Biotechnology in first move to treat acne with vaccine-based immunotherapy

Retrieved on: 
Wednesday, December 1, 2021
Skin, Safety, A-DNA, Acquisition, Bacteria, Acne, Antigen, Health, Doctor of Philosophy, Vaccine, Pain, Infection, RNA transfection, Cutibacterium, Sanofi Pasteur, Pharmaceutical industry

With this acquisition, Sanofi continues executing its global Play to Win strategy, pursuing growth opportunities and building an industry-leading vaccines pipeline.

Key Points: 
  • With this acquisition, Sanofi continues executing its global Play to Win strategy, pursuing growth opportunities and building an industry-leading vaccines pipeline.
  • ORI-001 is a therapeutic vaccine candidate for acne vulgaris based on recombinant proteins, which entered preliminary clinical studies in Q3 2021.
  • Welcoming Origimm within Sanofi expands our area of expertise by bringing extensive know-how in the field of skin microbiome and skin immunology.
  • With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe.

LexaGene’s MiQLab Detects Common Bioreactor Contaminant up to 300 Times Faster than Conventional Methods

Retrieved on: 
Tuesday, July 20, 2021
Propionibacterineae, Sexually transmitted diseases and infections, Infectious causes of cancer, Taxa, Bacterial vaginosis, Infertility, Mycoplasma, Cutibacterium, Medical specialties

Last month, LexaGene announced it could detect Cutibacterium acnes 36 to 168 times faster than conventional methods.

Key Points: 
  • Last month, LexaGene announced it could detect Cutibacterium acnes 36 to 168 times faster than conventional methods.
  • We expect the time benefit of MiQLab Mycoplasma Test to be up to 300 times faster than conventional methods.
  • LexaGenes results demonstrate that the MiQLab system can serve as a valid alternative to lengthy traditional methods for mycoplasma detection.
  • Given the MiQLab can be up to 300 times faster than traditional culture testing (~2 hours versus ~28 days) for a definitive result, the MiQLab can provide a significant time advantage for biopharmaceutical manufacturers.

BiomX Hosting Key Opinion Leader Symposium on Novel Phage Product for Acne Prone Skin

Retrieved on: 
Monday, September 9, 2019
Actinomycetales, Organ systems, Acneiform eruptions, RTT, Dermatology, Cutibacterium acnes, Gram-positive bacteria, Acne, Cutibacterium, Medicine, Bacteriophage

NESS ZIONA, Israel, Sept. 09, 2019 (GLOBE NEWSWIRE) -- BiomX Ltd., a microbiome company developing both natural and engineered phage therapies, today announced that it will host a Key Opinion Leader (KOL) meeting on a novel phage product for acne prone skin on Friday, September 13, 2019 in New York City.

Key Points: 
  • NESS ZIONA, Israel, Sept. 09, 2019 (GLOBE NEWSWIRE) -- BiomX Ltd., a microbiome company developing both natural and engineered phage therapies, today announced that it will host a Key Opinion Leader (KOL) meeting on a novel phage product for acne prone skin on Friday, September 13, 2019 in New York City.
  • The event will feature a presentation by KOL Leon H. Kircik, MD., Associate Clinical Professor at Icahn School of Medicine at Mount Sinai, who will discuss the current product landscape and unmet need for improving acne prone skin.
  • It contains a cocktail of phage that helps control skin microflora by targeting P. acnes, or Cutibacterium acnes, a bacteria associated with acne.
  • BiomXs product for acne-prone skin is anticipated to begin testing by the end of 2019.